NZ602041A - Heterocyclic inhibitors of histamine receptors for the treatment of disease - Google Patents
Heterocyclic inhibitors of histamine receptors for the treatment of diseaseInfo
- Publication number
- NZ602041A NZ602041A NZ602041A NZ60204111A NZ602041A NZ 602041 A NZ602041 A NZ 602041A NZ 602041 A NZ602041 A NZ 602041A NZ 60204111 A NZ60204111 A NZ 60204111A NZ 602041 A NZ602041 A NZ 602041A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- disease
- histamine receptors
- heterocyclic inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000000543 Histamine Receptors Human genes 0.000 title 1
- 108010002059 Histamine Receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- MBFFBGDJUTWNSJ-UHFFFAOYSA-N 5-piperazin-1-yl-8-thiophen-2-yltetrazolo[1,5-c]pyrimidine Chemical compound C1CNCCN1C(N1N=NN=C11)=NC=C1C1=CC=CS1 MBFFBGDJUTWNSJ-UHFFFAOYSA-N 0.000 abstract 1
- YBNACEUJMZQXFL-UHFFFAOYSA-N 5-piperazin-1-yl-8-thiophen-3-yltetrazolo[1,5-c]pyrimidine Chemical compound C1CNCCN1C(N1N=NN=C11)=NC=C1C1=CSC=C1 YBNACEUJMZQXFL-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31261510P | 2010-03-10 | 2010-03-10 | |
| PCT/US2011/027817 WO2011112766A2 (en) | 2010-03-10 | 2011-03-10 | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602041A true NZ602041A (en) | 2014-08-29 |
Family
ID=44564108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602041A NZ602041A (en) | 2010-03-10 | 2011-03-10 | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8569300B2 (https=) |
| EP (1) | EP2545058B1 (https=) |
| JP (1) | JP5888654B2 (https=) |
| KR (1) | KR20130016253A (https=) |
| CN (1) | CN102869666B (https=) |
| AR (1) | AR080496A1 (https=) |
| AU (1) | AU2011224316B2 (https=) |
| BR (1) | BR112012022211A2 (https=) |
| CA (1) | CA2791417A1 (https=) |
| ES (1) | ES2607125T3 (https=) |
| IL (1) | IL221829A (https=) |
| MX (1) | MX2012010404A (https=) |
| NZ (1) | NZ602041A (https=) |
| PH (1) | PH12012501783A1 (https=) |
| RU (1) | RU2012137180A (https=) |
| TW (1) | TW201200518A (https=) |
| UY (1) | UY33271A (https=) |
| WO (1) | WO2011112766A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859550B2 (en) * | 2011-09-12 | 2014-10-14 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| AU2014261070A1 (en) | 2013-05-02 | 2015-10-29 | Pfizer Inc. | Imidazo-triazine derivatives as PDE10 inhibitors |
| EP3290407B1 (en) | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| CA2969090C (en) | 2014-12-23 | 2023-05-02 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| AU2018208422B2 (en) | 2017-01-10 | 2021-11-11 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| MX2019008229A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MY200629A (en) | 2017-08-01 | 2024-01-06 | Theravance Biopharma R&D Ip Llc | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors |
| MX2020003579A (es) * | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) * | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| KR102614939B1 (ko) * | 2018-02-13 | 2023-12-19 | 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 |
| CN110655520A (zh) * | 2018-06-29 | 2020-01-07 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| CN110156786B (zh) * | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| JP2022506887A (ja) * | 2018-11-07 | 2022-01-17 | シャンハイ リンジーン バイオファーマ カンパニー リミテッド | 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用 |
| CN113272303B (zh) * | 2018-11-30 | 2024-09-17 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| PH12022550441A1 (en) * | 2019-08-22 | 2022-12-19 | Blueray Therapeutics Shanghai Co Ltd | Azaheteroaryl compound and application thereof |
| US12065444B2 (en) * | 2021-11-19 | 2024-08-20 | Crossignal Therapeutics, Inc. | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929812A (en) * | 1974-05-20 | 1975-12-30 | Squibb & Sons Inc | Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| JPWO2003028732A1 (ja) * | 2001-09-28 | 2005-01-13 | 協和醗酵工業株式会社 | 受容体拮抗剤 |
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| CN1310916C (zh) * | 2002-06-25 | 2007-04-18 | 协和发酵工业株式会社 | 双环类杂环化合物 |
| WO2004022060A2 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
| CA2569887A1 (en) * | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| PT2029602E (pt) * | 2006-05-31 | 2010-07-08 | Galapagos Nv | Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias |
| US20100016293A1 (en) * | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| WO2008031556A2 (en) | 2006-09-12 | 2008-03-20 | Ucb Pharma, S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| PL2247294T3 (pl) * | 2008-02-08 | 2014-09-30 | Basilea Pharmaceutica Ag | Makrolidy do leczenia chorób przez hamowanie PDE |
| TW201024297A (en) | 2008-09-10 | 2010-07-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| AU2009291783A1 (en) * | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| SG175195A1 (en) * | 2009-04-16 | 2011-11-28 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| EP2464647B1 (en) * | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| RS54772B1 (sr) | 2009-12-17 | 2016-10-31 | Merial Sas | Antiparazitska jedinjenja dihidroazola i kompozicije koje ih sadrže |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US20110237599A1 (en) * | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
-
2011
- 2011-03-07 TW TW100107575A patent/TW201200518A/zh unknown
- 2011-03-10 UY UY0001033271A patent/UY33271A/es not_active Application Discontinuation
- 2011-03-10 CN CN201180019492.3A patent/CN102869666B/zh not_active Expired - Fee Related
- 2011-03-10 PH PH1/2012/501783A patent/PH12012501783A1/en unknown
- 2011-03-10 RU RU2012137180/04A patent/RU2012137180A/ru not_active Application Discontinuation
- 2011-03-10 US US13/044,661 patent/US8569300B2/en not_active Expired - Fee Related
- 2011-03-10 KR KR1020127026253A patent/KR20130016253A/ko not_active Withdrawn
- 2011-03-10 JP JP2012557231A patent/JP5888654B2/ja not_active Expired - Fee Related
- 2011-03-10 BR BR112012022211A patent/BR112012022211A2/pt active Search and Examination
- 2011-03-10 NZ NZ602041A patent/NZ602041A/en not_active IP Right Cessation
- 2011-03-10 CA CA2791417A patent/CA2791417A1/en not_active Abandoned
- 2011-03-10 ES ES11754043.5T patent/ES2607125T3/es active Active
- 2011-03-10 WO PCT/US2011/027817 patent/WO2011112766A2/en not_active Ceased
- 2011-03-10 AU AU2011224316A patent/AU2011224316B2/en not_active Ceased
- 2011-03-10 EP EP11754043.5A patent/EP2545058B1/en not_active Not-in-force
- 2011-03-10 MX MX2012010404A patent/MX2012010404A/es active IP Right Grant
- 2011-03-11 AR ARP110100765A patent/AR080496A1/es not_active Application Discontinuation
-
2012
- 2012-09-06 IL IL221829A patent/IL221829A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012010404A (es) | 2013-05-20 |
| JP5888654B2 (ja) | 2016-03-22 |
| BR112012022211A2 (pt) | 2017-07-18 |
| TW201200518A (en) | 2012-01-01 |
| EP2545058B1 (en) | 2016-08-24 |
| ES2607125T3 (es) | 2017-03-29 |
| WO2011112766A3 (en) | 2012-01-19 |
| KR20130016253A (ko) | 2013-02-14 |
| JP2013522222A (ja) | 2013-06-13 |
| CN102869666A (zh) | 2013-01-09 |
| US20110237565A1 (en) | 2011-09-29 |
| PH12012501783A1 (en) | 2015-06-26 |
| WO2011112766A2 (en) | 2011-09-15 |
| US8569300B2 (en) | 2013-10-29 |
| UY33271A (es) | 2011-10-31 |
| AU2011224316A1 (en) | 2012-09-13 |
| CA2791417A1 (en) | 2011-09-15 |
| AR080496A1 (es) | 2012-04-11 |
| AU2011224316B2 (en) | 2016-09-15 |
| CN102869666B (zh) | 2015-09-09 |
| IL221829A (en) | 2014-11-30 |
| EP2545058A4 (en) | 2013-07-24 |
| RU2012137180A (ru) | 2014-04-20 |
| EP2545058A2 (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602041A (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| WO2011112687A3 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| WO2011112731A3 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| WO2010030757A3 (en) | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | |
| WO2010030785A3 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| WO2011080568A8 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| ZA200803940B (en) | [4-(Benzo[B]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | |
| EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| EA201101666A1 (ru) | 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
| MX2015008481A (es) | Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. | |
| PH12013500648A1 (en) | Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors | |
| IL211448A (en) | Use of bio-enhancers and/or photo-enhancers for preparing ophthalmic compositions comprising riboflavin or riboflavin phosphate for treating corneal ectasic disorders by corneal cross-linking | |
| EA201171306A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ | |
| MY170878A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| EA201201191A1 (ru) | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций | |
| PL2935274T3 (pl) | Pochodne 3-okso-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pirymidyny do leczenia chorób układu oddechowego | |
| NZ627361A (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| HK1216425A1 (zh) | 基於2，3-二氢咪唑并[1，2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂 | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
| HRP20182021T1 (hr) | Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2016 BY COMPUTER PACKAGES INC Effective date: 20150303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY COMPUTER PACKAGES INC Effective date: 20160318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20170302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180302 |
|
| LAPS | Patent lapsed |